|
Q3 FY2026
As of Jun 30, 2026
|
Q2 FY2026
As of Mar 31, 2026
|
Q1 FY2026
As of Dec 31, 2025
|
Q4 FY2025
As of Sep 30, 2025
|
Q3 FY2025
As of Jun 30, 2025
|
Q2 FY2025
As of Mar 31, 2025
|
Q1 FY2025
As of Dec 31, 2024
|
Q4 FY2024
As of Sep 30, 2024
|
Q3 FY2024
As of Jun 30, 2024
|
Q2 FY2024
As of Mar 31, 2024
|
Q1 FY2024
As of Dec 31, 2023
|
Q4 FY2023
As of Sep 30, 2023
|
Q3 FY2023
As of Jun 30, 2023
|
Q2 FY2023
As of Mar 31, 2023
|
Q1 FY2023
As of Dec 31, 2022
|
Q4 FY2022
As of Sep 30, 2022
|
Q3 FY2022
As of Jun 30, 2022
|
Q2 FY2022
As of Mar 31, 2022
|
Q1 FY2022
As of Dec 31, 2021
|
Q4 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts receivable - net | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Current assets | ||||||||||||||||||||
| Property, plant and equipment - net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other intangible assets - net | ||||||||||||||||||||
| Investments in partially-owned affiliates | ||||||||||||||||||||
| Assets held for sale | ||||||||||||||||||||
| Other noncurrent assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Shareholders' Equity | ||||||||||||||||||||
| Short-term debt | ||||||||||||||||||||
| Current portion of long-term debt | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued compensation and benefits | ||||||||||||||||||||
| Restructuring reserve | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||
| Long-term debt | ||||||||||||||||||||
| Liabilities held for sale | ||||||||||||||||||||
| Pension and postretirement benefits | ||||||||||||||||||||
| Other noncurrent liabilities | ||||||||||||||||||||
| Long-term liabilities | ||||||||||||||||||||
| Redeemable noncontrolling interests | ||||||||||||||||||||
| Preferred shares issued, par value $0.001; 100,000,000 shares authorized, Zero shares issued and outstanding at June 30, 2026 | ||||||||||||||||||||
| Ordinary shares issued, par value $0.001; $500,000,000 shares authorized, 77,096,932 shares issued and outstanding at June 30, 2026 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Shareholders' equity attributable to Adient | ||||||||||||||||||||
| Noncontrolling interests | ||||||||||||||||||||
| Total shareholders' equity | ||||||||||||||||||||
| Total liabilities and shareholders' equity |
Loading...
